301 related articles for article (PubMed ID: 18086159)
1. Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance.
Ljunggren C; Hedelin H; Salomonsson K; Ströberg P
J Sex Med; 2008 Feb; 5(2):469-75. PubMed ID: 18086159
[TBL] [Abstract][Full Text] [Related]
2. Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients.
Lombardi G; Macchiarella A; Cecconi F; Del Popolo G
J Sex Med; 2009 May; 6(5):1248-58. PubMed ID: 19210710
[TBL] [Abstract][Full Text] [Related]
3. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study.
Rubio-Aurioles E; Porst H; Eardley I; Goldstein I
J Sex Med; 2006 Nov; 3(6):1037-1049. PubMed ID: 17100937
[TBL] [Abstract][Full Text] [Related]
4. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors.
Tolrà JR; Campaña JMC; Ciutat LF; Miranda EF
J Sex Med; 2006 Sep; 3(5):901-909. PubMed ID: 16942534
[TBL] [Abstract][Full Text] [Related]
5. Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime.
Ströberg P; Hedelin H; Ljunggren C
Eur Urol; 2006 May; 49(5):900-7; discussion 907. PubMed ID: 16564126
[TBL] [Abstract][Full Text] [Related]
6. A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy.
Kim ED; Seftel AD; Goldfischer ER; Ni X; Burns PR
J Sex Med; 2014 Mar; 11(3):820-30. PubMed ID: 23841532
[TBL] [Abstract][Full Text] [Related]
7. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study.
Dean J; Hackett GI; Gentile V; Pirozzi-Farina F; Rosen RC; Zhao Y; Warner MR; Beardsworth A
J Sex Med; 2006 Jul; 3(4):650-661. PubMed ID: 16839321
[TBL] [Abstract][Full Text] [Related]
8. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
[TBL] [Abstract][Full Text] [Related]
9. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil.
Kim E; Seftel A; Goldfischer E; Baygani S; Burns P
Curr Med Res Opin; 2015 Feb; 31(2):379-89. PubMed ID: 25455432
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.
Ali ST
Pak J Pharm Sci; 2008 Jul; 21(3):275-81. PubMed ID: 18614424
[TBL] [Abstract][Full Text] [Related]
13. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
[TBL] [Abstract][Full Text] [Related]
14. The POTENT I randomized trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction.
Sperling H; Debruyne F; Boermans A; Beneke M; Ulbrich E; Ewald S
J Sex Med; 2010 Apr; 7(4 Pt 1):1497-507. PubMed ID: 20233275
[TBL] [Abstract][Full Text] [Related]
15. Vardenafil improves sexual function and treatment satisfaction in couples affected by erectile dysfunction (ED): a randomized, double-blind, placebo-controlled trial in PDE5 inhibitor-naïve men with ED and their partners.
Edwards D; Hackett G; Collins O; Curram J
J Sex Med; 2006 Nov; 3(6):1028-1036. PubMed ID: 17100936
[TBL] [Abstract][Full Text] [Related]
16. Timing of dose relative to sexual intercourse attempt in previous sildenafil citrate users treated with tadalafil.
Glina S; Sotomayor M; Gatchalian E; Yaman O; Dyachkova Y; Markey C; Kopernicky V
J Sex Med; 2006 Mar; 3(2):309-19. PubMed ID: 16490025
[TBL] [Abstract][Full Text] [Related]
17. Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy.
Salonia A; Gallina A; Zanni G; Briganti A; Dehò F; Saccà A; Suardi N; Barbieri L; Guazzoni G; Rigatti P; Montorsi F
Eur Urol; 2008 Mar; 53(3):564-70. PubMed ID: 17761385
[TBL] [Abstract][Full Text] [Related]
18. The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study.
Gökçe A; Halis F; Demirtas A; Ekmekcioglu O
BJU Int; 2011 Apr; 107(8):1274-7. PubMed ID: 21929518
[TBL] [Abstract][Full Text] [Related]
19. Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction.
Buvat J; Büttner H; Hatzimouratidis K; Vendeira PA; Moncada I; Boehmer M; Henneges C; Boess FG
J Sex Med; 2013 Jun; 10(6):1592-602. PubMed ID: 23551622
[TBL] [Abstract][Full Text] [Related]
20. Real-life safety and efficacy of vardenafil in the treatment of erectile dysfunction-results from 30,010 U.S. patients.
Cheng E
J Sex Med; 2007 Mar; 4(2):432-9. PubMed ID: 17087804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
